Crystalys Taps M&A Veteran as CFO for Gout Drug's Global Push

SAN DIEGO, CA – January 21, 2026 – Crystalys Therapeutics, a clinical-stage biopharmaceutical company, has significantly bolstered its executive team with the appointment of finance heavyweight Justin Thacker as its new Chief Financial Officer. The move signals a strategic escalation of the company's ambitions as it shepherds its promising gout therapy, dotinurad, through late-stage global clinical trials.

Thacker’s appointment comes on the heels of a massive $205 million Series A financing round, arming Crystalys with the capital needed to navigate the costly final phases of drug development. The company is advancing dotinurad in two pivotal Phase 3 trials, known as RUBY and TOPAZ, with the goal of securing regulatory approval and commercializing the drug in Western markets.

"We are incredibly excited to welcome Justin to our executive team," remarked James M. Mackay, Ph.D., CEO and President of Crystalys. "Justin brings exceptional expertise and a proven track record of financial stewardship and strategic transactions. His experience strengthens our organization, and Justin's contributions will play a critical role as we advance dotinurad through Phase 3 clinical trials and regulatory approval."

For his part, Thacker expressed enthusiasm for the company's trajectory, joining at a moment he described as transformative. "The initiation of our Phase 3 trials, RUBY and TOPAZ, evaluating dotinurad as a potential best-in-class gout therapy, together with the momentum from our $205 million Series A financing, marks a transformative moment for the Company," said Mr. Thacker. He added that he looks forward to helping "deliver a potentially safer, more effective treatment option to patients living with gout."

A Financial Architect for a Pivotal Moment

Justin Thacker is not just another finance executive; he is a seasoned strategist with a history of guiding biotech firms through their most critical financial milestones, including initial public offerings (IPOs) and lucrative acquisitions. His more than two decades in the life sciences sector have been marked by a series of high-value deals, making his appointment a clear statement of intent by Crystalys' board and its co-founders, Catalys Pacific and Novo Holdings.

Most recently, Thacker served as CFO at Capstan Therapeutics, where he was instrumental in navigating the company's rapid growth, culminating in its acquisition by pharmaceutical giant AbbVie in a deal valued at up to $2.1 billion. Before that, he was a key figure at Synthorx, where he supported its $150 million IPO and helped build the financial infrastructure that preceded its $2.5 billion sale to Sanofi. His resume is a roadmap of value creation, also including leadership roles at companies acquired by Teva Pharmaceuticals and Mallinckrodt.

This specific expertise is precisely what a company like Crystalys needs at this juncture. With a well-funded, late-stage clinical asset, the path forward involves complex financial planning. Thacker's experience in taking companies public and preparing them for M&A provides Crystalys with strategic flexibility. Whether the ultimate goal is to launch dotinurad as a standalone commercial entity or to position the company for a strategic partnership or acquisition, Thacker's playbook is tailor-made for the journey. His hiring is a move to assure investors that their substantial capital is being managed by a leader who knows how to execute an endgame.

Targeting a Persistent Void in Gout Treatment

The strategic financial maneuvers are in service of a significant medical goal: transforming the treatment landscape for millions of people suffering from gout. Gout is a painful and progressive form of inflammatory arthritis caused by high levels of uric acid, a condition known as hyperuricemia. While first-line treatments like allopurinol exist, a substantial portion of patients either cannot tolerate them or fail to reach target uric acid levels, leaving them at risk for debilitating gout flares and the formation of tophi—crystalized uric acid deposits in joints and tissues.

Crystalys' lead candidate, dotinurad, is a next-generation URAT1 inhibitor designed to address this unmet need. It works by increasing the excretion of uric acid through the kidneys. The company is positioning the once-daily oral therapy as a potential "best-in-class" option, aiming to provide superior safety and efficacy as a second-line treatment for patients who need better options.

What significantly de-risks the dotinurad program is its track record in Asia. The drug, originally invented by Fuji Yakuhin, has already secured regulatory approval and is being used by patients in Japan, China, the Philippines, and Thailand. This existing clinical data and real-world use provide a strong foundation of evidence supporting its safety and efficacy, giving Crystalys and its investors confidence as it embarks on the final, rigorous Phase 3 trials required for approval in the U.S. and Europe. The RUBY and TOPAZ studies will be the ultimate test of its best-in-class claims on a global stage, and a positive outcome could unlock a multi-billion-dollar market.

Biotech's Gravitational Pull on Top-Tier Talent

Thacker's move to Crystalys is emblematic of a broader trend within the biotechnology industry: the migration of highly accomplished, senior executives to clinical-stage companies. In an earlier era, such roles might have been seen as a step down from a C-suite position at a large, established pharmaceutical corporation. Today, they are viewed as premier opportunities for high-impact leadership.

The allure lies in the unique combination of risk and reward. For financial leaders like Thacker, joining a company like Crystalys offers the chance to build a financial strategy from a critical inflection point, directly influencing the company's trajectory toward an IPO, major acquisition, or commercial launch. It is a high-stakes environment where strategic decisions can generate immense value for the company, its investors, and ultimately, for patients awaiting new therapies.

This trend signals the maturation of the biotech ecosystem, where well-funded, private companies with promising late-stage assets are now able to compete for the same top-tier talent as their publicly traded, large-cap counterparts. The ability of Crystalys to attract a CFO with Thacker's deal-making pedigree speaks volumes about the perceived potential of dotinurad and the strength of its leadership team and backers. It suggests that the broader market sees Crystalys not just as a scientific endeavor, but as a serious commercial contender preparing for its debut on the world stage.